{
  "source": "PA-Notification-Tezspire.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1415-2\nProgram Prior Authorization/Notification\nMedications Tezspire™ (tezepelumab-ekko)*\n*This program applies to the prefilled pen for self-administration.\nP&T Approval Date 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nTezspire (tezepelumab) is indicated for the add-on maintenance treatment of adult and pediatric\npatients aged 12 years and older with severe asthma.\nLimitations of use:\nTezspire is not indicated for relief of acute bronchospasm of status asthmaticus.\n2. Coverage Criteriaa:\nA. Severe Asthma\n1. Initial Authorization\na. Tezspire will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Patient has been established on therapy with Tezspire under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nsevere asthma\n-AND-\n(b) Documentation of positive clinical response to Tezspire therapy\n-AND-\n(c) Tezspire is being used as add-on maintenance therapy\n-AND-\n(d) Patient is not receiving Tezspire in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab), Nucala (mepolizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\n© 2024 UnitedHealthcare Services, Inc.\n1\n-OR-\n(2) All of the following:\n(a) Diagnosis of severe asthma\n-AND-\n(b) Tezspire is being used as add-on maintenance therapy\n-AND-\n(c) Patient is not receiving Tezspire in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab), Nucala (mepolizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tezspire will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Tezspire therapy\n-AND-\n(2) Tezs",
    "will be issued for 12 months.\n2. Reauthorization\na. Tezspire will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Tezspire therapy\n-AND-\n(2) Tezspire is being used as add-on maintenance therapy\n-AND-\n(3) Patient is not receiving Tezspire in combination with any of the following:\n(a) Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab), Nucala (mepolizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n2\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limitations may be in place.\n• Medical Necessity may be in place.\n• The single-dose vial and pre-filled syringe for administration by a healthcare professional is\ntypically covered under the medical benefit. Please refer to the United Healthcare Medical\nBenefit Drug Policy: “Tezspire™ (tezepelumab-ekko).”\n3. References:\n1. Tezspire™ [package insert]. Thousand Oakes, CA: Amgen Inc.; May 2023.\nProgram Prior Authorization/Notification - Tezspire (tezepelumab)\nChange Control\n7/2023 New program.\n7/2024 Annual review. Specified existing prior authorization for under the\nmedical benefit. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}